SEC Form 4 · accession 0001209191-17-063884
AGIOS PHARMACEUTICALS, INC. · AGIO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Scott Biller
Officer — Chief Scientific Officer
Period of report
Dec 1, 2017
Accepted (ET)
Dec 5, 2017 · 4:09 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001439222
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common stock | Dec 1, 2017 | M | 2,146 | $31.64 | A | 8,410 | D | |
| Common stockF3 | Dec 1, 2017 | S | 600 | $59.89 | D | 7,810 | D | |
| Common stockF4 | Dec 1, 2017 | S | 846 | $60.63 | D | 6,964 | D | |
| Common stockF5 | Dec 1, 2017 | S | 700 | $61.76 | D | 6,264 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock options (right to buy)F6 | $31.64 | Dec 1, 2017 | M | 2,146 | D | — | Mar 4, 2024 | Common stock | 2,146 | 30,039 | D |
Explanation of responses
- F1This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- F2This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- F3The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $59.29 to $60.26. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- F4The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $60.35 to $61.06. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- F5The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $61.45 to $62.24. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- F6This option was granted on March 5, 2014. The shares underlying this option vest as to 25% of the shares on March 5, 2015, with the remaining 75% vesting in 36 equal monthly installments thereafter.